Efeito da ocitocina comparado ao promestrieno na síndrome geniturinária: estudo piloto randomizadoe e duplo-cego
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Tipo de documento: | Dissertação |
Idioma: | por |
Título da fonte: | Repositório Institucional da UNIFESP |
Texto Completo: | https://sucupira.capes.gov.br/sucupira/public/consultas/coleta/trabalhoConclusao/viewTrabalhoConclusao.jsf?popup=true&id_trabalho=11334890 https://repositorio.unifesp.br/handle/11600/68231 |
Resumo: | Prospective, double-blind and randomized pilot study to compare the effectiveness of oxytocin (OT) in relation to promestriene in improving sexual function, symptoms of vaginal atrophy as well as the clinical and histopathological examination of the vaginal wall in Genitourinary Syndrome of Menopause (GSM). 51 postmenopausal women presenting symptoms of GSM who met the inclusion and exclusion criteria were evaluated. They were randomized into two groups: group 1 (OT) with 25 patients and group 2 (promestriene) with 26. Patients received vaginal OT or promestriene gel and the FSFI domains (lubrication, satisfaction, and pain in sexual intercourse), visual clinical examination and vaginal wall thickness were evaluated before and after 90 days of treatment. Both groups, after the use of the medications showed significant improvement of the three FSFI domains evaluated (p<0.05). And when compared, no differences were revealed (p>0.05). However without statistical significance (p>0.05), the medications presented improvement in all parameters evaluated in the clinical examination. In the evaluation of the thickness of the vaginal epithelium, both treatments, when evaluated separately, presented an increase of the vaginal epithelium after their use however promestriene revealed better effectiveness than OT (p<0.05). Conclusion: After 90 days of vaginal application of oxytocin and promestriene, both were conformably effective in improving lubrication, satisfaction and pain domains obtained from the FSFI score, with no significant variance between them; Even without statistical significance, alterations in the vaginal mucosa visualized on clinical examination were improved; they were effective in increasing the thickness of the vaginal epithelium, with the promestriene showing superior performance. Yet, studies with a longer sample and prolonged time are still necessary to confirm clinical applicability. |
id |
UFSP_592bf5fe78b4406d45c0c0592f321dc1 |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br/:11600/68231 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
Efeito da ocitocina comparado ao promestrieno na síndrome geniturinária: estudo piloto randomizadoe e duplo-cegoGenitourinary SyndromePromestrieneOxytocinVulvovaginal AtrophyMenopauseSindrome GeniturináriaPromestrienoOcitocinaAtrofia VulvovaginalMenopausaProspective, double-blind and randomized pilot study to compare the effectiveness of oxytocin (OT) in relation to promestriene in improving sexual function, symptoms of vaginal atrophy as well as the clinical and histopathological examination of the vaginal wall in Genitourinary Syndrome of Menopause (GSM). 51 postmenopausal women presenting symptoms of GSM who met the inclusion and exclusion criteria were evaluated. They were randomized into two groups: group 1 (OT) with 25 patients and group 2 (promestriene) with 26. Patients received vaginal OT or promestriene gel and the FSFI domains (lubrication, satisfaction, and pain in sexual intercourse), visual clinical examination and vaginal wall thickness were evaluated before and after 90 days of treatment. Both groups, after the use of the medications showed significant improvement of the three FSFI domains evaluated (p<0.05). And when compared, no differences were revealed (p>0.05). However without statistical significance (p>0.05), the medications presented improvement in all parameters evaluated in the clinical examination. In the evaluation of the thickness of the vaginal epithelium, both treatments, when evaluated separately, presented an increase of the vaginal epithelium after their use however promestriene revealed better effectiveness than OT (p<0.05). Conclusion: After 90 days of vaginal application of oxytocin and promestriene, both were conformably effective in improving lubrication, satisfaction and pain domains obtained from the FSFI score, with no significant variance between them; Even without statistical significance, alterations in the vaginal mucosa visualized on clinical examination were improved; they were effective in increasing the thickness of the vaginal epithelium, with the promestriene showing superior performance. Yet, studies with a longer sample and prolonged time are still necessary to confirm clinical applicability.Estudo piloto prospectivo, duplo-cego e randomizado para comparar a eficácia da ocitocina (OT) em relação ao promestrieno na melhora da função sexual, dos sintomas de atrofia vaginal, do exame clínico e histopatológico da parede vaginal na Síndrome Geniturinária da Menopausa (GSM). Foram avaliadas 51 mulheres na pós-menopausa apresentando sintomas da GSM e que satisfaziam os critérios de inclusão e exclusão. Foram randomizados em dois grupos: grupo 1 (OT) com 25 pacientes e grupo 2 (promestrieno) com 26. As pacientes recebiam gel vaginal de OT ou promestrieno e os domínios do FSFI (lubrificação, satisfação e dor na relação sexual), o exame clínico visual e a espessura da parede vaginal eram avaliados antes e após 90 dias de tratamento. Ambos os grupos, após o uso das medicações mostraram melhora significante dos três domínios do FSFI avaliados (p<0,05) e quando comparados, não revelaram diferença (p>0,05). No exame clínico, as medicações revelaram melhora em todos os parâmetros avaliados, porém sem significância estatística (p>0,05). Na avaliação da espessura do epitélio vaginal ambos os tratamentos, quando avaliados separadamente, mostraram aumento após as medicações (p< 0,05), porém o promestrieno revelou melhor eficácia que a OT (p<0,05). Conclusão: Após 90 dias da aplicação vaginal da ocitocina e do promestrieno, concluímos que ambos foram eficazes, sem diferença significante entre eles, na melhora dos domínios lubrificação, satisfação e dor obtidos do escore FSFI; promoveram melhora das alterações da mucosa vaginal visualizadas ao exame clínico, porém sem significância estatística; foram eficazes para o aumento da espessura do epitélio vaginal, havendo superioridade do promestrieno. No entanto, estudos com maior casuística e por tempo prolongado ainda são necessários para confirmar a aplicabilidade clínica.Dados abertos - Sucupira - Teses e dissertações (2021)Universidade Federal de São Paulo (UNIFESP)Silva, Ismael Dale Cotrim Guerreiro Da [UNIFESP]Universidade Federal de São PauloSantos, Liani Patricia Andrade [UNIFESP]2023-06-27T12:32:41Z2023-06-27T12:32:41Z2021info:eu-repo/semantics/masterThesisinfo:eu-repo/semantics/publishedVersion50 p.application/pdfhttps://sucupira.capes.gov.br/sucupira/public/consultas/coleta/trabalhoConclusao/viewTrabalhoConclusao.jsf?popup=true&id_trabalho=11334890LIANI PATRICIA ANDRADE SANTOS-A.pdfhttps://repositorio.unifesp.br/handle/11600/68231porinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-08-12T22:10:15Zoai:repositorio.unifesp.br/:11600/68231Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-08-12T22:10:15Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.none.fl_str_mv |
Efeito da ocitocina comparado ao promestrieno na síndrome geniturinária: estudo piloto randomizadoe e duplo-cego |
title |
Efeito da ocitocina comparado ao promestrieno na síndrome geniturinária: estudo piloto randomizadoe e duplo-cego |
spellingShingle |
Efeito da ocitocina comparado ao promestrieno na síndrome geniturinária: estudo piloto randomizadoe e duplo-cego Santos, Liani Patricia Andrade [UNIFESP] Genitourinary Syndrome Promestriene Oxytocin Vulvovaginal Atrophy Menopause Sindrome Geniturinária Promestrieno Ocitocina Atrofia Vulvovaginal Menopausa |
title_short |
Efeito da ocitocina comparado ao promestrieno na síndrome geniturinária: estudo piloto randomizadoe e duplo-cego |
title_full |
Efeito da ocitocina comparado ao promestrieno na síndrome geniturinária: estudo piloto randomizadoe e duplo-cego |
title_fullStr |
Efeito da ocitocina comparado ao promestrieno na síndrome geniturinária: estudo piloto randomizadoe e duplo-cego |
title_full_unstemmed |
Efeito da ocitocina comparado ao promestrieno na síndrome geniturinária: estudo piloto randomizadoe e duplo-cego |
title_sort |
Efeito da ocitocina comparado ao promestrieno na síndrome geniturinária: estudo piloto randomizadoe e duplo-cego |
author |
Santos, Liani Patricia Andrade [UNIFESP] |
author_facet |
Santos, Liani Patricia Andrade [UNIFESP] |
author_role |
author |
dc.contributor.none.fl_str_mv |
Silva, Ismael Dale Cotrim Guerreiro Da [UNIFESP] Universidade Federal de São Paulo |
dc.contributor.author.fl_str_mv |
Santos, Liani Patricia Andrade [UNIFESP] |
dc.subject.por.fl_str_mv |
Genitourinary Syndrome Promestriene Oxytocin Vulvovaginal Atrophy Menopause Sindrome Geniturinária Promestrieno Ocitocina Atrofia Vulvovaginal Menopausa |
topic |
Genitourinary Syndrome Promestriene Oxytocin Vulvovaginal Atrophy Menopause Sindrome Geniturinária Promestrieno Ocitocina Atrofia Vulvovaginal Menopausa |
description |
Prospective, double-blind and randomized pilot study to compare the effectiveness of oxytocin (OT) in relation to promestriene in improving sexual function, symptoms of vaginal atrophy as well as the clinical and histopathological examination of the vaginal wall in Genitourinary Syndrome of Menopause (GSM). 51 postmenopausal women presenting symptoms of GSM who met the inclusion and exclusion criteria were evaluated. They were randomized into two groups: group 1 (OT) with 25 patients and group 2 (promestriene) with 26. Patients received vaginal OT or promestriene gel and the FSFI domains (lubrication, satisfaction, and pain in sexual intercourse), visual clinical examination and vaginal wall thickness were evaluated before and after 90 days of treatment. Both groups, after the use of the medications showed significant improvement of the three FSFI domains evaluated (p<0.05). And when compared, no differences were revealed (p>0.05). However without statistical significance (p>0.05), the medications presented improvement in all parameters evaluated in the clinical examination. In the evaluation of the thickness of the vaginal epithelium, both treatments, when evaluated separately, presented an increase of the vaginal epithelium after their use however promestriene revealed better effectiveness than OT (p<0.05). Conclusion: After 90 days of vaginal application of oxytocin and promestriene, both were conformably effective in improving lubrication, satisfaction and pain domains obtained from the FSFI score, with no significant variance between them; Even without statistical significance, alterations in the vaginal mucosa visualized on clinical examination were improved; they were effective in increasing the thickness of the vaginal epithelium, with the promestriene showing superior performance. Yet, studies with a longer sample and prolonged time are still necessary to confirm clinical applicability. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021 2023-06-27T12:32:41Z 2023-06-27T12:32:41Z |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
masterThesis |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://sucupira.capes.gov.br/sucupira/public/consultas/coleta/trabalhoConclusao/viewTrabalhoConclusao.jsf?popup=true&id_trabalho=11334890 LIANI PATRICIA ANDRADE SANTOS-A.pdf https://repositorio.unifesp.br/handle/11600/68231 |
url |
https://sucupira.capes.gov.br/sucupira/public/consultas/coleta/trabalhoConclusao/viewTrabalhoConclusao.jsf?popup=true&id_trabalho=11334890 https://repositorio.unifesp.br/handle/11600/68231 |
identifier_str_mv |
LIANI PATRICIA ANDRADE SANTOS-A.pdf |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
50 p. application/pdf |
dc.publisher.none.fl_str_mv |
Universidade Federal de São Paulo (UNIFESP) |
publisher.none.fl_str_mv |
Universidade Federal de São Paulo (UNIFESP) |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
biblioteca.csp@unifesp.br |
_version_ |
1814268454763495424 |